Cargando…

Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis

The aims of this subanalysis of the COLM trial [NCT00454662] were to compare visit-to-visit variability (VVV) of blood pressure (BP) between age groups and between two treatment combinations, that is, the angiotensin II receptor blocker, olmesartan combined with a calcium channel blocker (CCB), or a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rakugi, Hiromi, Ogihara, Toshio, Saruta, Takao, Kawai, Tatsuo, Saito, Ikuo, Teramukai, Satoshi, Shimada, Kazuyuki, Katayama, Shigehiro, Higaki, Jitsuo, Odawara, Masato, Tanahashi, Norio, Kimura, Genjiroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570687/
https://www.ncbi.nlm.nih.gov/pubmed/26066644
http://dx.doi.org/10.1097/HJH.0000000000000668
_version_ 1782390244262281216
author Rakugi, Hiromi
Ogihara, Toshio
Saruta, Takao
Kawai, Tatsuo
Saito, Ikuo
Teramukai, Satoshi
Shimada, Kazuyuki
Katayama, Shigehiro
Higaki, Jitsuo
Odawara, Masato
Tanahashi, Norio
Kimura, Genjiroh
author_facet Rakugi, Hiromi
Ogihara, Toshio
Saruta, Takao
Kawai, Tatsuo
Saito, Ikuo
Teramukai, Satoshi
Shimada, Kazuyuki
Katayama, Shigehiro
Higaki, Jitsuo
Odawara, Masato
Tanahashi, Norio
Kimura, Genjiroh
author_sort Rakugi, Hiromi
collection PubMed
description The aims of this subanalysis of the COLM trial [NCT00454662] were to compare visit-to-visit variability (VVV) of blood pressure (BP) between age groups and between two treatment combinations, that is, the angiotensin II receptor blocker, olmesartan combined with a calcium channel blocker (CCB), or a diuretic and to investigate the effect of VVV of BP on cardiovascular events in elderly hypertensive patients. METHODS: Hypertensive patients ages 65–84 years with a history of and/or risk factors for cardiovascular disease were randomized to receive treatment with olmesartan along with either a CCB or a diuretic for at least 3 years. This subanalysis comprised 4876 patients who had their office BP measured at least three occasions (median nine occasions) during the follow-up period. VVV of BP was defined by several metrics including the within-individual standard deviation of every visit during the follow-up period. RESULTS: VVV of SBP was larger in the very elderly group (75–84 years) than in the elderly group (65–74 years). VVV of SBP was smaller in the olmesartan along with CCB group than in the olmesartan along with diuretic group, especially in very elderly patients and also isolated systolic hypertensive patients. The incidence rate of primary endpoint increased along with an increment in the SD of SBP in all of the age and treatment groups. CONCLUSION: VVV of SBP may mediate the preferable effect of combination of angiotensin II receptor blocker along with CCB on cardiovascular events in the very elderly and also isolated systolic hypertensive patients.
format Online
Article
Text
id pubmed-4570687
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-45706872015-09-30 Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis Rakugi, Hiromi Ogihara, Toshio Saruta, Takao Kawai, Tatsuo Saito, Ikuo Teramukai, Satoshi Shimada, Kazuyuki Katayama, Shigehiro Higaki, Jitsuo Odawara, Masato Tanahashi, Norio Kimura, Genjiroh J Hypertens ORIGINAL PAPERS: Therapeutic aspects The aims of this subanalysis of the COLM trial [NCT00454662] were to compare visit-to-visit variability (VVV) of blood pressure (BP) between age groups and between two treatment combinations, that is, the angiotensin II receptor blocker, olmesartan combined with a calcium channel blocker (CCB), or a diuretic and to investigate the effect of VVV of BP on cardiovascular events in elderly hypertensive patients. METHODS: Hypertensive patients ages 65–84 years with a history of and/or risk factors for cardiovascular disease were randomized to receive treatment with olmesartan along with either a CCB or a diuretic for at least 3 years. This subanalysis comprised 4876 patients who had their office BP measured at least three occasions (median nine occasions) during the follow-up period. VVV of BP was defined by several metrics including the within-individual standard deviation of every visit during the follow-up period. RESULTS: VVV of SBP was larger in the very elderly group (75–84 years) than in the elderly group (65–74 years). VVV of SBP was smaller in the olmesartan along with CCB group than in the olmesartan along with diuretic group, especially in very elderly patients and also isolated systolic hypertensive patients. The incidence rate of primary endpoint increased along with an increment in the SD of SBP in all of the age and treatment groups. CONCLUSION: VVV of SBP may mediate the preferable effect of combination of angiotensin II receptor blocker along with CCB on cardiovascular events in the very elderly and also isolated systolic hypertensive patients. Lippincott Williams & Wilkins 2015-10 2015-10-01 /pmc/articles/PMC4570687/ /pubmed/26066644 http://dx.doi.org/10.1097/HJH.0000000000000668 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle ORIGINAL PAPERS: Therapeutic aspects
Rakugi, Hiromi
Ogihara, Toshio
Saruta, Takao
Kawai, Tatsuo
Saito, Ikuo
Teramukai, Satoshi
Shimada, Kazuyuki
Katayama, Shigehiro
Higaki, Jitsuo
Odawara, Masato
Tanahashi, Norio
Kimura, Genjiroh
Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis
title Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis
title_full Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis
title_fullStr Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis
title_full_unstemmed Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis
title_short Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis
title_sort preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: colm study subanalysis
topic ORIGINAL PAPERS: Therapeutic aspects
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570687/
https://www.ncbi.nlm.nih.gov/pubmed/26066644
http://dx.doi.org/10.1097/HJH.0000000000000668
work_keys_str_mv AT rakugihiromi preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT ogiharatoshio preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT sarutatakao preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT kawaitatsuo preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT saitoikuo preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT teramukaisatoshi preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT shimadakazuyuki preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT katayamashigehiro preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT higakijitsuo preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT odawaramasato preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT tanahashinorio preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis
AT kimuragenjiroh preferableeffectsofolmesartancalciumchannelblockertoolmesartandiureticonbloodpressurevariabilityinveryelderlyhypertensioncolmstudysubanalysis